Detalhe da pesquisa
1.
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Blood
; 143(6): 496-506, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879047
2.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Blood
; 141(19): 2307-2315, 2023 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36821768
3.
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.
Cancer
; 130(6): 876-885, 2024 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37985359
4.
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Blood
; 140(8): 851-860, 2022 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35679476
5.
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma.
Blood
; 140(5): 504-515, 2022 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512184
6.
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Am J Hematol
; 99(5): 880-889, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38504387
7.
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Breast Cancer Res
; 25(1): 62, 2023 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37280713
8.
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
Br J Haematol
; 200(1): 35-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36068929
9.
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
Blood
; 137(23): 3272-3276, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534891
10.
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031807
11.
IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
J Immunol
; 206(8): 1966-1975, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722878
12.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Lancet Oncol
; 23(1): 91-103, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895487
13.
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma.
Haematologica
; 107(7): 1555-1566, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34758610
14.
Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma.
Haematologica
; 106(2): 495-512, 2021 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32029507
15.
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.
Haematologica
; 106(10): 2667-2672, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32732355
16.
Chimeric antigen receptor T-cell therapy toxicities.
Br J Clin Pharmacol
; 87(6): 2414-2424, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32463929
17.
Correction: IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
J Immunol
; 212(3): 500, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088809
18.
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Br J Haematol
; 189(4): 650-660, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32180219
19.
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med
; 377(26): 2531-2544, 2017 12 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29226797
20.
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.
Haematologica
; 105(7): 1907-1913, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31601688